Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
There were probably over 100 posters related to prostate cancer presented at the ASCO meeting today (Sunday, May 31), so you will have to pardon us for not even attempting to report on all this vast variety of data. Rather, we have attempted to select out the papers that seem to offer the most interesting [...]
Filed under: Diagnosis, Drugs in development, Risk | Tagged: abiraterone acetate, PCA3 | Leave a Comment »
In this commentary we will discuss four additional, significant papers presented yesterday in the major oral session on new prostate cancer studies.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen deprivation, conservative management, nomogram, risk, survival | Leave a Comment »
On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology.
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100, OGX-011, PROSTVAC-VF, vaccines | Leave a Comment »
Today’s news reports address issues such as: Pro-PSA (a pecursor molecule to PSA itself) A review of development-stage markers for prostate cancer detection Understanding the pathology report A Phase I trial of high-dose testosterone in men with metatstatic CRPC
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: atypia, detection, markers, pathology, pro-PSA, risk, testosterone therapy | Leave a Comment »
Today’s prostate cancer news reports address: A review of data on the potential for prostate cancer prevention A review of appropriate strategic options for rebiopsy in patients at risk Prostate cancer in men with a PSA < 2.5 ng/ml The sequential use of multiple cycles of docetaxel therapy
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: docetaxel, low PSA, Prevention, rebiopsy, risk, sequential | Leave a Comment »
Dr. Aaron Katz has been practicing cryotherapy at Columbia University Medical Center in New York since 1993, so one could reasonably expect him to have a sophisticated appreciation for the pros and cons of this technique.
Filed under: Management, Treatment | Tagged: cryotherapy, focal therapy, localized | Leave a Comment »
Every so often you come across something so far “out of left field” that just possibly it may make some sense. So having said that, let me declare my ignorance.
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: melatonin | 2 Comments »
Today’s news reports cover such items as: Identification of prostate cancer cells in urine Prognosis after radiation therapy The effect of bisphenol A on prostate cancer therapy The appropriateness of primary androgen deprivation for localized prostate cancer Data from clinical trials of Phase II clinical trial of docetaxel + samarium-153 lexidronam and cyclophosphamide + dexamethasone [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation therapy, bisphenol A, cyclophosphamide, Diagnosis, docetaxel, primary, prognosis, risk, samarium-153 | Leave a Comment »
According to Phase I/II clinical trial data published on Wednesday in the on-line version of the Journal of Clinical Oncology, 9/24 subjects in one of the abiraterone prostate cancer studies demonstrated a decrease in tumor size. Maybe this helps to explain why Johnson & Johnson is willing to pay over $900 million for the company.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, casteration-resistant prostate cancer, CRPC | Leave a Comment »
Many readers may be interested in two articles on the “screening controversy” in the May issue of Oncology News International.
Filed under: Diagnosis, Risk | Tagged: PSA, screening | 4 Comments »
In today’s news reports there are items on: Genetic modifications and prostate cancer risk and development Situation-specific prostate biopsy strategies A viral vector-prodrug combination in treatment of local and locally advanced disease Docetaxel + 153Sm lexidronam in metastatic CRPC
Filed under: Diagnosis, Drugs in development, Management, Risk | Tagged: biopsy, CB1954, development, docetaxel, gene, risk, samarium-153 lexidronam, vector | Leave a Comment »
Recently, a UK-based team (Challacombe et al.) working at a major London teaching hospital reported very poor 2-year follow-up data after treating a series of 31 newly diagnosed and 12 salvage patients with high-intensity focused ultrasound (HIFU) using second-generation Ablatherm equipment. They stated in their original paper that they had suspended their HIFU program as [...]
Filed under: Management, Treatment, Uncategorized | Tagged: HIFU, high-intensity focused ultrasound | 3 Comments »
We have taken advantage of the long weekend to carry out a complete overhaul of the major section on prostate cancer “Risk + Prevention” (see green tabs at top of this page).
Filed under: Prevention, Risk | Comments Off
There is some media buzz around publication of the results of a Phase I trial of Zyflamend, a commercially available herbal concoction that is supposed to be able to “affect the inflammation responses and may serve an important function in promoting normal cell growth in the colon, pancreas, breast tissue, and other organ systems.” However, [...]
Filed under: Prevention | Tagged: HG-PIN, Zyflamend | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site